NXS Stock Overview
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia.
Next Science Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.01|
|52 Week High||AU$1.55|
|52 Week Low||AU$0.70|
|1 Month Change||22.42%|
|3 Month Change||18.13%|
|1 Year Change||-31.99%|
|3 Year Change||-65.76%|
|5 Year Change||n/a|
|Change since IPO||-25.19%|
Recent News & Updates
|NXS||AU Medical Equipment||AU Market|
Return vs Industry: NXS underperformed the Australian Medical Equipment industry which returned -17.2% over the past year.
Return vs Market: NXS underperformed the Australian Market which returned -7.9% over the past year.
|NXS Average Weekly Movement||11.5%|
|Medical Equipment Industry Average Movement||11.5%|
|Market Average Movement||10.6%|
|10% most volatile stocks in AU Market||17.5%|
|10% least volatile stocks in AU Market||4.7%|
Stable Share Price: NXS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: NXS's weekly volatility (12%) has been stable over the past year.
About the Company
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for surgical infection management; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site infections.
Next Science Fundamentals Summary
|NXS fundamental statistics|
Is NXS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NXS income statement (TTM)|
|Cost of Revenue||US$2.01m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.044|
|Net Profit Margin||-104.49%|
How did NXS perform over the long term?See historical performance and comparison
Is NXS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NXS?
Other financial metrics that can be useful for relative valuation.
|What is NXS's n/a Ratio?|
Price to Sales Ratio vs Peers
How does NXS's PS Ratio compare to its peers?
|NXS PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
NXS Next Science
Price-To-Sales vs Peers: NXS is good value based on its Price-To-Sales Ratio (16.7x) compared to the peer average (17.6x).
Price to Earnings Ratio vs Industry
How does NXS's PE Ratio compare vs other companies in the AU Medical Equipment Industry?
Price-To-Sales vs Industry: NXS is expensive based on its Price-To-Sales Ratio (16.7x) compared to the Australian Medical Equipment industry average (6.6x)
Price to Sales Ratio vs Fair Ratio
What is NXS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||16.7x|
|Fair PS Ratio||32.1x|
Price-To-Sales vs Fair Ratio: NXS is good value based on its Price-To-Sales Ratio (16.7x) compared to the estimated Fair Price-To-Sales Ratio (32.1x).
Share Price vs Fair Value
What is the Fair Price of NXS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NXS (A$1.01) is trading below our estimate of fair value (A$8.85)
Significantly Below Fair Value: NXS is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
How is Next Science forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NXS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.8%).
Earnings vs Market: NXS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: NXS is expected to become profitable in the next 3 years.
Revenue vs Market: NXS's revenue (51.9% per year) is forecast to grow faster than the Australian market (5.7% per year).
High Growth Revenue: NXS's revenue (51.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NXS's Return on Equity is forecast to be low in 3 years time (18.8%).
Discover growth companies
How has Next Science performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NXS is currently unprofitable.
Growing Profit Margin: NXS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NXS is unprofitable, and losses have increased over the past 5 years at a rate of 8.7% per year.
Accelerating Growth: Unable to compare NXS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NXS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (32.6%).
Return on Equity
High ROE: NXS has a negative Return on Equity (-86.84%), as it is currently unprofitable.
Discover strong past performing companies
How is Next Science's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: NXS's short term assets ($10.2M) exceed its short term liabilities ($1.5M).
Long Term Liabilities: NXS's short term assets ($10.2M) exceed its long term liabilities ($1.4M).
Debt to Equity History and Analysis
Debt Level: NXS has more cash than its total debt.
Reducing Debt: Insufficient data to determine if NXS's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NXS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if NXS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is Next Science current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NXS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NXS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NXS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NXS's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NXS has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ms. Judith Mitchell, also known as Judy, M.B.A, serves as Managing Director and Chief Executive Officer of Next Science Limited since August 2017 and serves as its Executive Director since October 20, 2017...
CEO Compensation Analysis
Compensation vs Market: Judy's total compensation ($USD202.78K) is about average for companies of similar size in the Australian market ($USD279.73K).
Compensation vs Earnings: Judy's compensation has been consistent with company performance over the past year.
Experienced Management: NXS's management team is considered experienced (4.2 years average tenure).
Experienced Board: NXS's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.5%.
Next Science Limited's employee growth, exchange listings and data sources
- Name: Next Science Limited
- Ticker: NXS
- Exchange: ASX
- Founded: 2012
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: AU$216.938m
- Shares outstanding: 214.79m
- Website: https://www.nextscience.com
- Next Science Limited
- The Zenith Building, Tower A
- Suite 1902
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/07 00:00|
|End of Day Share Price||2022/08/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.